Briefing
Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.
Clearance of ctDNA at 6 months was observed in 3/7 (43%) in the observation arm and 1/9 (11%) in the chemotherapy arm (P=0.98). The phase II endpoint was not met; enrollment was halted under prespecified stopping rules based on the original assay. No improvement in clearance was seen after 6 months of chemotherapy in ctDNA-detected resected stage IIA colon cancer. The abstract notes future integral-biomarker trials must account for assay specificity in this population.
- n: 635 randomized (318 observation, 317 ctDNA-directed); phase II clearance analysis used the first 16 patients with baseline ctDNA detected
- Assay: Guardant LUNAR (mutations plus colon cancer-specific methylation)